Future Revenue Future Revenue Future Revenue Accrued expenses and other current liabilities Accrued Liabilities, Current Range [Domain] Statistical Measurement [Domain] Total current assets Assets, Current Inventory valuation reserves Inventory Valuation Reserves Research and development Research and Development Expense Potential commercial milestone payments under agreement PotentialCommercialMilestonePaymentsUnderAgreement Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] DRI Healthcare Acquisitions LP (DRI) DRI Healthcare Acquisitions LP (DRI) [Member] DRI Healthcare Acquisitions LP (DRI) Revenue from Contract with Customer [Abstract] Supplemental Cash Flow Information Supplemental Cash Flow Information [Abstract] Award Type [Domain] Award Type [Domain] Revenue, remaining performance obligation, expected timing of satisfaction Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Beginning Balance (in shares) Ending Balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Entity Filer Category Entity Filer Category Statement of Stockholders' Equity [Abstract] Schedule of Stock Options Roll Forward Schedule of Stock Options Roll Forward [Table Text Block] Statement [Table] Statement [Table] Investments, Debt and Equity Securities [Abstract] Current Fiscal Year End Date Current Fiscal Year End Date Manufacturing Services Manufacturing Services [Member] Manufacturing Services Potential proceeds from royalties (percent) ProceedsfromRoyaltiesPercent Accounts payable Accounts Payable, Current Weighted- Average Remaining Contractual Term, Exercisable (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Net proceeds from sale of future royalties Net proceeds from sale of future royalties Net proceeds from sale of future royalties NIAID NationalInstituteOfAllergyAndInfectiousDiseasesMember Corporate debt securities Corporate Debt Securities [Member] Marketable securities Investments Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Shares, Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Non-refundable upfront payment, net of tax withholding Nonrefundable Upfront Fees, Net Of Tax Withholding Nonrefundable Upfront Fees, Net Of Tax Withholding Liability related to future royalty [Line Items] Liability related to future royalty [Line Items] Liability related to future royalty [Line Items] Stockholders' Equity Equity [Text Block] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Aggregate Intrinsic Value, Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Aggregate Intrinsic Value, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Proceeds from issuance of common stock, net of offering costs Proceeds from Issuance of Common Stock Type of Arrangement and Non-arrangement Transactions [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Deferred revenue Increase (Decrease) in Contract with Customer, Liability Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Proceeds from Sale of Machinery and Equipment Proceeds from Sale of Machinery and Equipment Depreciation and amortization expense Depreciation, Depletion and Amortization Current liabilities: Liabilities, Current [Abstract] Sanofi Sanofi [Member] Sanofi Incyte MGA012 Agreement IncyteMGA012AgreementMember Statement of Financial Position [Abstract] Total stockholders' equity Equity, Attributable to Parent Subsequent Event Type [Domain] Subsequent Event Type [Domain] Weighted-Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Diluted net loss per common share (in usd per share) Earnings Per Share, Diluted Unrealized gain (loss) on investments Unrealized Gain (Loss) on Investments Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Liability related to future royalties [Abstract] Liability related to future royalties Liability related to future royalties Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Royalty Monetization Arrangement Liability Related To Sale Of Future Royalties [Text Block] Liability Related To Sale Of Future Royalties Subsequent Events [Abstract] Options outstanding (in shares) Shares, Outstanding, Beginning Balance (in shares) Shares, Outstanding, Ending Balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number RevenueFromRoyalityAgreementsMember RevenueFromRoyalityAgreementsMember [Member] RevenueFromRoyalityAgreementsMember Trading Symbol Trading Symbol RevenuesFromCMOAgreementsMember RevenuesFromCMOAgreementsMember [Member] RevenuesFromCMOAgreementsMember Weighted- Average Exercise Price, Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted-average grant-date fair value of options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value License And Collaboration Agreements [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Level 2 Fair Value, Inputs, Level 2 [Member] Net loss Net loss Net income (loss) Net Income (Loss) Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Non-refundable upfront payment NonRefundableUpfrontFees Finished goods Inventory, Finished Goods, Gross Beginning balance (in shares) Ending balance (in shares) Shares, Issued Liabilities and stockholders' equity Liabilities and Equity [Abstract] Milestones Value Added Tax Milestones Value Added Tax Milestones Value Added Tax Stock plan related activity Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Stockholders' equity: Equity, Attributable to Parent [Abstract] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Shares, Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Deferred revenue Contract with Customer, Liability Document Fiscal Period Focus Document Fiscal Period Focus Basic and Diluted Loss Per Common Share Computation Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of product sales Cost of Goods and Services Sold Provention PRV3279 Provention PRV3279 [Member] Provention PRV3279 Weighted-average exercise price of stock options outstanding (in dollars per share) Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share) Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Proceeds from stock option exercises and ESPP purchases ProceedsfromStockOptionsExercisedAndESPPPurchases Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Common Stock Common Stock [Member] Weighted- Average Exercise Price, Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Level 1 Fair Value, Inputs, Level 1 [Member] Shares, Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Maximum amount available for issuance Common Stock, Maximum Amount Available For Issuance Common Stock, Maximum Amount Available For Issuance City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Net Income (Loss) Per Share Earnings Per Share [Text Block] Product and Service [Axis] Product and Service [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Royalty Royalty [Member] Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Incyte MGA012 Clinical Services Incyte MGA012 Clinical Services [Member] Incyte MGA012 Clinical Services Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities Financial Assets Measured at Fair Value on a Recurring Basis Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Entity Small Business Entity Small Business Weighted average common shares outstanding: Weighted Average Number of Shares Outstanding, Basic [Abstract] Minimum Minimum [Member] Local Phone Number Local Phone Number Accounts receivable Increase (Decrease) in Accounts Receivable Stock plan activity (in shares) Stock Issued During Period Shares Stock Plan Activity Number of shares issued due to stock plan related activity. Property, equipment and software, net Property, Plant and Equipment, Net Measurement Frequency [Axis] Measurement Frequency [Axis] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Nature of Operations Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Potential development and regulatory milestone payments under agreement PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement Contract Manufacturing Contract Manufacturing [Member] Contract Manufacturing Restricted Stock Units Restricted Stock Units (RSUs) [Member] Schedule of RSU Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Lease liabilities Increase (Decrease) in Operating Lease Liability Taxes paid related to net share settlement of equity awards Payment, Tax Withholding, Share-Based Payment Arrangement At the Market Offering At The Market Offering [Member] At The Market Offering 2022 Gilead Collaboration And License Agreement 2022 Gilead Collaboration And License Agreement [Member] 2022 Gilead Collaboration And License Agreement Asset Purchase Agreement Asset Purchase Agreement [Member] Asset Acquisition Agreement U.S. Treasury securities US Treasury Securities [Member] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities In-licensing arrangement Commitments and Contingencies Disclosure [Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Premium received on stock purchase PremiumReceivedOnStockPurchase PremiumReceivedOnStockPurchase Nonrefundable payment tax withholding Nonrefundable Payment Tax Withholding Nonrefundable Payment Tax Withholding Liability related to the sale of future royalties and related interest expense Liability related to future royalties and related interest expense [Policy Text Block] Liability related to future royalties and related interest expense Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Accumulated Deficit Retained Earnings [Member] Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Amortization of premiums and discounts on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Total liabilities and stockholders' equity Liabilities and Equity Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Other non current assets Other Assets, Noncurrent Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Gilead Gilead [Member] Gilead Basic net loss per common share (in usd per share) Earnings Per Share, Basic Right-of-use asset Operating Lease, Right-of-Use Asset RevenuesFromCMOAmendmentAgreement RevenuesFromCMOAmendmentAgreement [Member] RevenuesFromCMOAmendmentAgreement Accounting Policies [Abstract] Offering period Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period Sale of Stock [Domain] Sale of Stock [Domain] Number of shares sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Accumulated other comprehensive income (loss) AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax Revenues Revenues Estimated variable consideration Revenue, Information Used To Assess Variable Consideration, Amount Revenue, Information Used To Assess Variable Consideration, Amount Intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Product and Service [Domain] Product and Service [Domain] Inventory Increase (Decrease) in Inventories Entity Address, City or Town Entity Address, City or Town Accounts payable Increase (Decrease) in Accounts Payable and Other Operating Liabilities Collaborative and other agreements RevenueFromCollaborativeAgreementsMember Research and Development Research and Development Expense [Member] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Zai Lab Agreement, TRIDENT molecule Zai Labs Collaboration And License Agreement, TRIDENT molecule [Member] Zai Labs Collaboration And License Agreement, TRIDENT molecule Fair value of shares vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Weighted- Average Remaining Contractual Term, Vested and expected to vest (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Stock options excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Plan Name [Domain] Plan Name [Domain] Document Quarterly Report Document Quarterly Report Liability Related to Future Royalty Liability Related to Future Royalty [Table Text Block] Liability Related to Future Royalty Interest expense Interest Expense Total unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Property, equipment and software included in accounts payable or accruals Capital Expenditures Incurred but Not yet Paid Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Cost of manufacturing services Cost of manufacturing services Cost of manufacturing services Document Transition Report Document Transition Report General and Administrative General and Administrative Expense [Member] Share-based compensation, number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Weighted- Average Remaining Contractual Term, Outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Revenue Collaboration And Other Agreements Disclosure [Text Block] StockIncentivePlan2023Member StockIncentivePlan2023Member [Member] StockIncentivePlan2023Member Securities Fair Value Debt Securities, Available-for-Sale Transaction Cost Transaction Cost Transaction Cost Entity File Number Entity File Number I-Mab Biopharma Collaboration And License Agreement Clinical Supply I-Mab Biopharma Collaboration And License Agreement Clinical Supply [Member] I-Mab Biopharma Collaboration And License Agreement Clinical Supply Lease liabilities Operating Lease, Liability, Current Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Development and regulatory milestones recognized Development And Regulatory Milestone Payments Under Agreement, Recognized Development And Regulatory Milestone Payments Under Agreement, Recognized Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Allowance for credit loss related to available-for-sale debt securities Debt Securities, Available-for-Sale, Allowance for Credit Loss Liability related to future royalties [Abstract] Liability related to future royalties [Abstract] Liability related to future royalties [Abstract] Proceeds from sale and maturities of marketable securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Entity Shell Company Entity Shell Company Zai Lab Agreement, Margetuximab Zai Labs Collaboration And License Agreement, Margetuximab [Member] Zai Labs Collaboration And License Agreement, Margetuximab Adjustments to reconcile net income (loss) to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Synaffix B.V. Synaffix B.V. [Member] Synaffix B.V. Deferred transaction costs Deferred transaction costs Deferred transaction costs Counterparty Name [Domain] Counterparty Name [Domain] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents 2018 Zai Lab Agreement 2018 Zai Lab Collaboration And License Agreement [Member] 2018 Zai Lab Collaboration And License Agreement Asset Class [Axis] Asset Class [Axis] 2016 Employee Stock Purchase Plan TwoThousandSixteenEmployeeStockPurchasePlanMember Proceeds from sale of future royalties Proceeds from sale of future royalties Proceeds from sale of future royalties Government-sponsored enterprises US Government-sponsored Enterprises Debt Securities [Member] Sales of stock purchase price (in dollars per share) Sale of Stock, Price Per Share Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Deferred revenue Deferred revenue, current Contract with Customer, Liability, Current One Time Millstone Credit One Time Millstone Credit One Time Millstone Credit Valuation Assumptions Using the Black-Scholes Option-Pricing Model Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Forfeited or expired (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Security Exchange Name Security Exchange Name Subsequent Event Type [Axis] Subsequent Event Type [Axis] Cash received for options exercised Proceeds from Stock Options Exercised Total assets measured at fair value Assets, Fair Value Disclosure Upfront Payment Upfront Payment Upfront Payment Proceeds of stock sale Sale of Stock, Consideration Received on Transaction Loss on disposal of assets Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Incyte Corporation IncyteCorporationMember Non-cash lease expense Operating Lease, Noncash Expense Operating Lease, Noncash Expense Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Weighted- Average Exercise Price, Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Work in process Inventory, Work in Process, Gross Forfeited or expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Unrecognized compensation expense recognition period (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total costs and expenses Costs and Expenses Maximum Maximum [Member] Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Revenues From Grants RevenuesFromGrantsMember Document Type Document Type Aggregate Intrinsic Value, Outstanding, Ending Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Entity Address, Address Line One Entity Address, Address Line One Payroll deduction percentage EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent Entity Registrant Name Entity Registrant Name Interest and other income Other Nonoperating Income Stock options and restricted stock units Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Other non current assets Increase (Decrease) in Other Operating Assets Subsequent Event [Table] Subsequent Event [Table] Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Other non-cash items Other Noncash Income (Expense) Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-Sale Document Period End Date Document Period End Date Weighted- Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted- Average Exercise Price, Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Non-cash interest expense recognized Non-cash interest expense recognized Non-cash interest expense recognized Entity Central Index Key Entity Central Index Key Subsequent Event Subsequent Event [Member] Annual Fixed Payments Total Annual Fixed Payments Total Annual Fixed Payments Stock-based compensation expense Share-Based Payment Arrangement, Expense Income Statement [Abstract] Issuance of common stock, net of offering costs (in shares) Number of shares issued or sold (in shares) Stock Issued During Period, Shares, New Issues Costs and expenses: Costs and Expenses [Abstract] Shares, Forfeited or expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure I-Mab I-Mab Biopharma [Member] I-Mab Biopharma Number of commercialized molecules NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement One-time credit paid, percent Collaboration Arrangement, One-time Credit Paid, Percent Collaboration Arrangement, One-time Credit Paid, Percent Issuance of common stock, net of offering costs Stock Issued During Period, Value, New Issues Gain on modification of debt Gain on modification of debt Gain on royalty monetization arrangement Gain on royalty monetization arrangement Equity [Abstract] Beginning Balance (in dollars per share) Ending Balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Additional Payments Additional Annual Fixed Payments Additional Annual Fixed Payments Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Inventory, Net Inventory Disclosure [Text Block] In-licensing arrangement[Table] In-Licensing arrangement [Table] In-Licensing arrangement Class of Stock [Line Items] Class of Stock [Line Items] Amendment Flag Amendment Flag Money market funds Money Market Funds [Member] Provention PRV031 Provention PRV031 [Member] Provention PRV031 Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Inventory, net Total inventory, net Inventory, Net Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Common stock purchased (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Range [Axis] Statistical Measurement [Axis] Assets: Assets, Fair Value Disclosure [Abstract] Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current I-Mab Biopharma Collaboration and License Agreement I-Mab Biopharma Collaboration And License Agreement [Member] I-Mab Biopharma Collaboration And License Agreement Principal payments on royalty monetization arrangement Principal payments on royalty monetization arrangement Principal payments on royalty monetization arrangement Net income (loss) per common share: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Product sales, net Product [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Diluted weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Inventory Disclosure [Abstract] Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accumulated deficit Retained Earnings (Accumulated Deficit) Commitments and Contingencies Disclosure [Abstract] Purchases of property, equipment and software Payments to Acquire Property, Plant, and Equipment Additional paid-in capital Additional Paid in Capital, Common Stock Collaborative agreement transaction price CollaborativeAgreementTransactionPrice Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Additional Paid-In Capital Additional Paid-in Capital [Member] Current assets: Assets, Current [Abstract] Weighted- Average Exercise Price, Expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Total assets Assets Entity Address, State or Province Entity Address, State or Province Counterparty Name [Axis] Counterparty Name [Axis] Stock plan related activity Stock Issued During Period Value Stock Plan Activity Value of shares issued due to stock plan related activity. Cover [Abstract] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Zai Labs Zai Lab [Member] Zai Lab Subsequent Event Subsequent Events [Text Block] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Fair Value Measurements, Recurring Basis Fair Value, Recurring [Member] Unrealized loss on investments OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding In-Licensing arrangement [Line Items] In-Licensing arrangement [Line Items] In-Licensing arrangement [Line Items] Other non current liabilities Other Liabilities, Noncurrent Exercised (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Revenues From License Agreements RevenuesFromLicenseAgreementsMember Government agreements RevenueFromGovernmentAgreementsMember Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share Provention License Agreement Provention License Agreement [Member] Provention License Agreement Number of performance obligations Number Of Performance Obligations Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Asset Class [Domain] Asset Class [Domain] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Variable consideration recognized Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Sale of Stock [Axis] Sale of Stock [Axis] Liability related to future royalty [Table] Liability related to future royalty [Table] Liability related to future royalty [Table] Equity Component [Domain] Equity Component [Domain] Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Purchase price of common stock percent of the fair market value Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Basic weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Extension term Revenue, Performance Obligation, Extension Term Revenue, Performance Obligation, Extension Term Loss from operations Operating Income (Loss) Total potential value TotalPotentialValueUnderAgreement 2021 Zai Lab Agreements 2021 Zai Lab Agreements [Member] 2021 Zai Lab Agreements Accumulated Other Comprehensive Income (Loss) AOCI Including Portion Attributable to Noncontrolling Interest [Member] Total liabilities Liabilities Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Maximum amount available for issuance, increase Common Stock, Maximum Amount Available For Issuance, Increase Common Stock, Maximum Amount Available For Issuance, Increase Revenues: Revenues [Abstract] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Liability related to future royalties [Roll Forward] Liability related to future royalties [Roll Forward] Liability related to future royalties Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Provention Bio Provention Bio [Member] Provention Bio Deferred revenue, net of current portion Contract with Customer, Liability, Noncurrent Collaboration And Other Agreements [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Statement [Line Items] Statement [Line Items] Plan Name [Axis] Plan Name [Axis] Shares, Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Collaboration and License Agreements [Abstract] Collaboration and License Agreements [Abstract] Earnings Per Share [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Available-for-sale Marketable Securities Debt Securities, Available-for-Sale [Table Text Block] Common stock, $0.01 par value -- 125,000,000 shares authorized, 61,938,493 and 61,701,467 shares outstanding at June 30, 2023 and December 31, 2022, respectively Common Stock, Value, Issued Selling, general and administrative General and Administrative Expense Potential target nomination, option fees and milestone payments Potential target nomination, option fees and milestone payments Potential target, nomination, option fees and milestone payments Organization, Consolidation and Presentation of Financial Statements [Abstract]